ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 28, 2019 14:05 ET
|
Schall Law
LOS ANGELES, Aug. 28, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics,...
MacroGenics to Participate in Upcoming Investor Conferences
August 08, 2019 16:01 ET
|
MacroGenics, Inc.
Rockville, MD, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results
July 31, 2019 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., July 31, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Second Quarter 2019 Financial Results Conference Call
July 24, 2019 16:01 ET
|
MacroGenics, Inc.
Rockville, Md., July 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
July 17, 2019 16:01 ET
|
MacroGenics, Inc.
Enrollment of Phase 1 monotherapy expansion cohort completed; presentation of data expected 2H2019End of Phase 1 meeting requested with FDA to discuss program and future development plansInitiation of...
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
July 10, 2019 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
MacroGenics to Participate in Jefferies Healthcare Conference
May 30, 2019 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, May 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
May 28, 2019 16:30 ET
|
MacroGenics, Inc.
Rockville, MD, May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
May 15, 2019 17:07 ET
|
MacroGenics, Inc.
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy)Oral abstract will be presented at American...
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
May 01, 2019 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...